Salt and aldosterone do not get along with each other: Implication of mineralocorticoid receptors in the profibrotic action of aldosterone

Kidney International

Volumn 81, Issue 1, 2012, Pages 118-

  Armanini, Decio ^a   Calò, Lorenzo ^a   Fiore, Cristina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CANRENOATE POTASSIUM; CANRENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SODIUM CHLORIDE; SPIRONOLACTONE;

ENZYME ACTIVATION; HEART MUSCLE FIBROSIS; HUMAN; HYPOALDOSTERONISM; KIDNEY FIBROSIS; LETTER; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; VASCULAR FIBROSIS;

EID: 83655181229     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.362     Document Type: Letter

References (5)

1. Bertocchio JP, Warnock DG, Jaisser FJ. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011; 79: 1051-1060.
2. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
3. Calo LA, Zaghetto F, Pagnin E et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI 1 and p22phox in human mononuclear leukocytes. J Clin Endocrinol Metab 2004; 89: 1973-1976. (Pubitemid 38507960)
4. Armanini D, Strasser T, Weber PC. Characterization af aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol 1985; 48(3 Pt 1): E388-E390. (Pubitemid 15076603)
5. Armanini D, Fiore C, Pellati D. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension 2007; 50: e69-e70. (Pubitemid 47442748)